Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors

被引:121
作者
Gupta, Vikas [2 ]
Eapen, Mary [1 ]
Brazauskas, Ruta [3 ]
Carreras, Jeanette
Aljurf, Mahmoud [4 ]
Gale, Robert Peter [5 ]
Hale, Gregory A. [6 ]
Ilhan, Osman [7 ]
Passweg, Jakob R. [8 ]
Ringden, Olle [9 ]
Sabloff, Mitchell [10 ]
Schrezenmeier, Hubert [11 ,12 ]
Socie, Gerard [13 ]
Marsh, Judith C. W. [14 ]
机构
[1] Med Coll Wisconsin, Ctr Stat, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
[2] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[3] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA
[4] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
[5] Celgene Corp, Summit, NJ USA
[6] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA
[7] Ankara Univ, Ibni Sina Hosp, TR-06100 Ankara, Turkey
[8] Univ Hosp Geneva, Geneva, Switzerland
[9] Karolinska Univ Hosp, Stockholm, Sweden
[10] Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada
[11] Univ Ulm, Ulm, Germany
[12] German Red Cross Blood Transfus Serv Baden Wurtte, IKT Ulm, Ulm, Germany
[13] Hop St Louis, Paris, France
[14] Kings Coll Hosp London, London, England
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷 / 12期
关键词
severe aplastic anemia; transplantation; patient age; HLA-identical sibling donor; overall survival; STEM-CELL TRANSPLANTATION; VERSUS-HOST-DISEASE; IMMUNOSUPPRESSIVE THERAPY; ANTITHYMOCYTE GLOBULIN; EUROPEAN GROUP; CYCLOPHOSPHAMIDE; FLUDARABINE; PATHOPHYSIOLOGY; CYCLOSPORINE; SURVIVAL;
D O I
10.3324/haematol.2010.026682
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transplantation from an HLA-matched sibling is the treatment of choice for young patients with acquired severe aplastic anemia. For older patients, the acceptable upper age limit for transplantation as first-line treatment varies. The current analysis, therefore, sought to identify age or ages at transplantation at which survival differed. Design and Methods We studied the effect of patients' age, adjusting for other significant factors affecting outcomes, in 1307 patients with severe aplastic anemia after HLA-matched sibling transplantation using logistic and Cox regression analysis. Age categories (< 20 years, 20-40 years, > 40 years) were determined using Martingale residual plots for overall survival and categories based on differences in survival. Results Patients aged over 40 years old were more likely to have had immunosuppressive therapy, a poor performance score and a longer interval between diagnosis and transplantation. Neutrophil recovery was similar in all age groups but patients aged over 40 years had a lower likelihood of platelet recovery compared to patients aged less than 20 years (OR 0.45, P=0.01) but not compared to those aged 20-40 years (OR 0.60, P=0.10). Compared to the risk of mortality in patients aged less than 20 years, mortality risks were higher in patients over 40 years old (RR 2.70, P < 0.0001) and in those aged 20-40 years (RR 1.69, P < 0.0001). The mortality risk was also higher in patients aged over 40 years than in those 20-40 years old (RR 1.60, P=0.008). Conclusions Mortality risks increased with age. Risks were also higher in patients with a poor performance score and when the interval between diagnosis and transplantation was longer than 3 months, implying earlier referral would be appropriate when this treatment option is being considered.
引用
收藏
页码:2119 / 2125
页数:7
相关论文
共 27 条
[1]   Long-term outcome after bone marrow transplantation for severe aplastic anemia [J].
Ades, L ;
Mary, JY ;
Robin, M ;
Ferry, C ;
Porcher, R ;
Esperou, H ;
Ribaud, P ;
Devergie, A ;
Traineau, R ;
Gluckman, E ;
Socié, G .
BLOOD, 2004, 103 (07) :2490-2497
[2]   Treatment strategies for patients with severe aplastic anemia [J].
Bacigalupo, A. .
BONE MARROW TRANSPLANTATION, 2008, 42 (Suppl 1) :S42-S44
[3]   Treatment of acquired severe aplastic anemia:: Bone marrow transplantation compared with immunosuppressive therapy -: The European Group for Blood and Marrow Transplantation Experience [J].
Bacigalupo, A ;
Brand, R ;
Oneto, R ;
Bruno, B ;
Socié, G ;
Passweg, J ;
Locasciulli, A ;
Van Lint, MT ;
Tichelli, A ;
McCann, S ;
Marsh, J ;
Ljungman, P ;
Hows, J ;
Marin, P ;
Schrezenmeier, H .
SEMINARS IN HEMATOLOGY, 2000, 37 (01) :69-80
[4]   Current results of bone marrow transplantation in patients with acquired severe aplastic anemia -: Report of the European group for blood and marrow transplantation [J].
Bacigalupo, A ;
Oneto, R ;
Bruno, B ;
Socié, G ;
Passweg, J ;
Locasciulli, A ;
Van Lint, MT ;
Tichelli, A ;
McCann, S ;
Marsh, J ;
Ljungman, P ;
Hows, J ;
Marin, P ;
Schrezenmeier, H .
ACTA HAEMATOLOGICA, 2000, 103 (01) :19-25
[5]  
Bagby Grover C, 2004, Hematology Am Soc Hematol Educ Program, P318
[6]   Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy [J].
Doney, K ;
Leisenring, W ;
Storb, R ;
Appelbaum, FR .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (02) :107-+
[7]   Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection [J].
Dulley, FL ;
Vigorito, AC ;
Aranha, FJP ;
Sturaro, D ;
Ruiz, MA ;
Saboya, R ;
Macedo, MCMA ;
Da Silva, RL ;
Chamone, DAF ;
Mehta, J ;
Bacigalupo, A ;
De Souza, CA .
BONE MARROW TRANSPLANTATION, 2004, 33 (01) :9-13
[8]   Pathophysiology and treatment of graft-versus-host disease [J].
Flowers, MED ;
Kansu, E ;
Sullivan, KM .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (05) :1091-+
[9]   Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia [J].
Frickhofen, N ;
Heimpel, H ;
Kaltwasser, JP ;
Schrezenmeier, H .
BLOOD, 2003, 101 (04) :1236-1242
[10]   Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia [J].
George, B. ;
Mathews, V. ;
Viswabandya, A. ;
Kavitha, M. L. ;
Srivastava, A. ;
Chandy, M. .
BONE MARROW TRANSPLANTATION, 2007, 40 (01) :13-18